S&P Futures
4,271.75 -9.25 (-0.22%) Dow Futures
33,652.00 -66.00 (-0.20%) Nasdaq Futures
13,547.75 -30.00 (-0.22%) Russell 2000 Futures
2,011.70 -5.20 (-0.26%) Crude Oil
91.92 -0.17 (-0.18%) Gold
1,817.10 +1.60 (+0.09%)
Axonics, Inc. (AXNX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 70.08 |
| Open | 70.30 |
| Bid | 68.85 x 900 |
| Ask | 82.28 x 1300 |
| Day's Range | 69.29 - 72.48 |
| 52 Week Range | 38.41 - 79.81 |
| Volume | |
| Avg. Volume | 585,720 |
| Market Cap | 3.351B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.83 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.63 |
- Zacks
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Business Wire
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
IRVINE, Calif., August 05, 2022--Axonics, Inc. (Nasdaq: AXNX) ("Axonics"), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offer
- Zacks
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
